PRESS RELEASE: BG Medicine Files US Registration Statement with SEC in Support of Euronext Amsterdam IPO

BG Medicine, Inc. today announced it has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission (SEC) for a proposed Initial Public Offering (IPO) of its common stock. All of the shares to be offered will be sold by the company. The number of shares to be sold and the price range for the offering have not yet been determined. BG Medicine intends to apply for its common stock to list and trade on Euronext Amsterdam by NYSE Euronext under the symbol "BGMDX".

Cowen International Limited and Fortis will be acting as joint global coordinators and joint book-runners for the offering. Leerink Swann & Company will act as co-manager.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. In addition, the offering is subject to approval of the prospectus by the Netherlands Authority for the Financial Markets (AFM), the entity that supervises the operation of the financial markets in the Netherlands. The registration statement is available at

BG Medicine securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective and the AFM has approved the prospectus.

This release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. A copy of the prospectus, when available, may be obtained from the prospectus department of Cowen International Limited, 1 Snowden Street, 11th floor, London EC2A 2DQ United Kingdom or Fortis Bank (Nederland) N.V., Rokin 55, 1012 KK, Amsterdam, The Netherlands.

About BG Medicine

BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine discovers biomarkers and develops its diagnostic product candidates using its proprietary, versatile, and scalable technology platform which integrates and automates the precise measurement, analysis, characterization and interpretation of thousands of proteins, metabolites and nucleic acids collected from bodily fluids. BG Medicine is leveraging its technology platform in multiple biomarker initiatives and collaborations with TNO, Philips, major pharmaceutical companies, other healthcare organizations and the U.S. Food and Drug Administration.